Ticker brief
EVMN
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
13
authors 14d
10
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-21 → 2026-07-01 · now -0.25 (−1 bearish … +1 bullish)
Who spoke10
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BiopharmIQ | B | · | 3 | +0.12 |
| @semodough | C | -0.75 | 2 | +0.25 |
| @MartinShkreli | B | -0.77 | 1 | +0.70 |
| @TWFeditor | C | +0.57 | 1 | -0.35 |
| @fwpharma | B | +0.22 | 1 | -0.60 |
| @PrismMarketView | C | · | 1 | -0.35 |
| @AnthonySandford | C | · | 1 | -0.50 |
| @BPharmCatalyst | C | · | 1 | -0.60 |
| @Optimalinvestme | C | +0.15 | 1 | -0.20 |
| @IPODave | B | +1.63 | 1 | -0.25 |
Recent signals13of 13 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-01 | @IPODave | -0.25 | Says EVMN disappointed, surprised not down more, needs digging on bio IPO trajectory. | · | tweet ↗ |
| 2026-06-29 | @Optimalinvestme | -0.20 | Arabic list of biggest decliners for monitoring; max tickers capped at six. | · | tweet ↗ |
| 2026-06-29 | @BPharmCatalyst | -0.60 | EVO756 missed primary endpoint in Phase 2b CSU trial and CSU development ended. | · | tweet ↗ |
| 2026-06-29 | @AnthonySandford | -0.50 | Unusual volume and most-active dashboard lists volume spikes and percentage moves. | · | tweet ↗ |
| 2026-06-29 | @PrismMarketView | -0.35 | Lists mid-day movers with percentage moves across several names. | · | tweet ↗ |
| 2026-06-29 | @fwpharma | -0.60 | Evommune oral drug failed a mid-stage urticaria study. | · | tweet ↗ |
| 2026-06-29 | @semodough | +0.45 | Cantor believes EVMN should be valued significantly higher based on IL-18 in atopic dermatitis. | · | tweet ↗ |
| 2026-06-29 | @TWFeditor | -0.35 | Reports EVMN surrendered YTD gains. | · | tweet ↗ |
| 2026-06-29 | @MartinShkreli | +0.70 | Long EVMN on today's drop as a new position. — Explicitly says long EVMN on the drop, new position, with drug-development thesis. | · | tweet ↗ |
| 2026-06-27 | @semodough | +0.05 | Notes expected Ph2B CSU readout for EVO756 likely next week. | · | tweet ↗ |
| 2026-06-21 | @BiopharmIQ | +0.15 | Identifies EVMN and MLTX as likely major catalyst events that can move stock by over 20%. | · | tweet ↗ |
| 2026-06-21 | @BiopharmIQ | +0.20 | Shows hedge fund ownership count for EVMN and MLTX at 8 of 36 funds. | · | tweet ↗ |
| 2026-06-21 | @BiopharmIQ | +0.00 | Biotech catalyst watchlist for Phase 2 and Phase 3 readouts in Q2/H1 2026. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.